康泰医学(300869) - 300869康泰医学投资者关系管理信息20250915

Group 1: Product Development and Innovation - The company has developed key technologies in "embodied motion rehabilitation intelligent equipment," which won the 2024 Hebei Provincial Science and Technology Progress Award [2] - Ongoing projects include medical endoscopes, in vitro diagnostic products, and dental consumables to meet changing market demands [3] - The company focuses on high-end products and has optimized existing products in ECG, blood pressure, and blood oxygen categories while actively developing new products [2] Group 2: Market Strategy and Expansion - The company is enhancing its domestic market presence through deep cooperation with leading e-commerce platforms to increase brand awareness [4] - Plans to expand into Southeast Asia, Africa, and South America are underway, targeting the growing demand for cost-effective medical devices in these regions [6] - The company aims to improve global market coverage and penetration through localized construction and cross-border e-commerce initiatives [6] Group 3: Financial Performance and Governance - The company's performance in the second quarter was not profitable, with profits primarily from the first quarter; management remains confident in future growth [7] - Shareholder reductions in holdings are attributed to personal financial needs and comply with legal regulations [7] - Recent changes in the supervisory board were part of normal governance optimization and did not involve any collective board incidents [4] Group 4: Technological Advancements - The company is actively investing in AI technology, focusing on integrating AI with medical devices and developing algorithms for patient monitoring [7] - Innovations include multi-mode temperature detection and pulse wave-based respiratory rate calculations, contributing to the advancement of smart healthcare [7]